Home Health Agency EBITDA Valuation Multiples: What Buyers Are Paying in 2024
Medicare-certified home health agencies trade at 3.5x–6x EBITDA. Learn what drives premium valuations and where most lower middle market agencies land.
Home health agencies in the $1M–$5M revenue range typically trade at 3.5x–6x EBITDA, with Medicare certification, clean compliance history, and diversified payor mix driving valuations toward the upper end. Strong CMS star ratings, a stable patient census, and a non-owner-dependent management team are the clearest signals buyers use to justify premium pricing. Agencies burdened by open RAC audits, high staff turnover, or single-referral-source dependency typically trade at or below 4x.
Home Health Agency EBITDA Multiple Ranges by Tier
| Business Tier | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed / Below Market | $150K–$300K | 3.0x–3.5x | Open CMS survey deficiencies, unresolved billing audits, heavy owner dependency, or low star ratings. Buyers require significant post-close remediation and price accordingly. |
| Average / Market Rate | $300K–$500K | 3.5x–4.5x | Active Medicare certification, acceptable payor mix, adequate staffing, but limited management depth or moderate referral concentration. Typical SBA-financed transaction range. |
| Above Average | $500K–$750K | 4.5x–5.5x | Strong CMS star ratings, diversified payor mix including private pay or managed care, documented SOPs, and a capable clinical leadership team not reliant on the owner. |
| Premium / Strategic | $750K+ | 5.5x–6.5x | Exceptional outcomes data, multi-county geographic footprint, long-standing hospital referral relationships, and clean compliance history. Primary targets for PE roll-up platforms. |
What Drives Home Health Agency Multiples
CMS Star Rating & Clinical Outcomes
High impactAgencies with 4–5 star ratings and low rehospitalization rates command premium multiples. Strong OASIS scores signal clinical quality and reduce post-acquisition compliance risk for buyers.
Payor Mix Diversification
High impactHeavy Medicare or Medicaid concentration increases reimbursement risk under PDGM. Agencies with 20–30% private pay or managed care contracts trade at meaningfully higher multiples.
Management Team Independence
High impactBuyers heavily discount owner-dependent agencies. A licensed DON, billing manager, and scheduler operating without daily owner involvement can add 0.5x–1.0x to the final multiple.
Clean Compliance & Billing History
High impactNo open RAC audits, low claim denial rates, and a third-party billing compliance audit covering three years significantly reduce buyer risk and support higher valuations.
Patient Census Stability
Medium impactAn active census of 75–150 patients with long average length of service and institutionalized referral relationships demonstrates recurring revenue and reduces post-close attrition risk.
Recent Market Trends
PDGM reimbursement pressure has compressed margins at smaller agencies, pushing some below viable EBITDA thresholds. PE-backed roll-ups remain aggressive acquirers in the 4.5x–6x range for agencies with clean compliance and geographic expansion value. SBA 7(a) financing remains accessible for individual buyers at 3.5x–4.5x, but lenders now require thorough billing compliance documentation pre-approval. Labor cost inflation has become a top diligence concern, with buyers scrutinizing wage rates against regional benchmarks before finalizing offers.
Sample Home Health Agency Transactions
Medicare-certified agency in the Southeast, 90 active patients, 4-star CMS rating, diversified payor mix, strong DON in place, no open audits
$420,000
EBITDA
4.8x
Multiple
$2,016,000
Price
Midwest agency with Medicare and Medicaid payor mix, 65 active patients, owner-operator clinical director, moderate compliance documentation, single hospital referral source
$280,000
EBITDA
3.7x
Multiple
$1,036,000
Price
Mid-Atlantic agency with 120+ active patients, managed care contracts, 4.5-star rating, independent management team, acquired by regional PE-backed platform
$690,000
EBITDA
5.8x
Multiple
$4,002,000
Price
EBITDA Valuation Estimator
Get your Home Health Agency business value range instantly
Industry: Home Health Agency · Multiples based on 3.5x–4.5x (Average / Market Rate)
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
What EBITDA multiple should I expect for my Medicare-certified home health agency?
Most lower middle market agencies sell between 3.5x and 5.5x EBITDA. Clean compliance history, strong CMS star ratings, and management independence are the primary drivers pushing multiples above 4.5x.
How does the CHOW process affect home health agency valuation?
CHOW delays of 60–180 days introduce closing risk. Buyers often structure deals with holdbacks or earnouts tied to successful CMS re-enrollment, which can effectively reduce the net price received at closing.
Can I use an SBA loan to buy a home health agency?
Yes. Home health agencies are SBA 7(a) eligible. Typical structures include 80% SBA financing, 10% seller note, and 10% buyer equity injection, assuming clean financials and no open compliance investigations.
What kills home health agency valuations most often in due diligence?
Open RAC audits, unresolved CMS overpayment demands, high staff turnover, and single-referral-source concentration are the most common value killers discovered during diligence, often triggering price reductions of 20–40%.
More Home Health Agency Guides
Find Home Health Agency businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
Start finding deals — freeNo credit card required